Document

0001492658-18-000048.txt : 20181107 0001492658-18-000048.hdr.sgml : 20181107 20181107160637 ACCESSION NUMBER: 0001492658-18-000048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20181107 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20181107 DATE AS OF CHANGE: 20181107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Wright Medical Group N.V. CENTRAL INDEX KEY: 0001492658 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 980509600 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35065 FILM NUMBER: 181166324 BUSINESS ADDRESS: STREET 1: PRINS BERNHARDPLEIN 200 CITY: AMSTERDAM STATE: P7 ZIP: 1097JB BUSINESS PHONE: 901-867-4317 MAIL ADDRESS: STREET 1: 1023 CHERRY ROAD CITY: MEMPHIS STATE: TN ZIP: 38117 FORMER COMPANY: FORMER CONFORMED NAME: Tornier N.V. DATE OF NAME CHANGE: 20110201 FORMER COMPANY: FORMER CONFORMED NAME: Tornier B.V. DATE OF NAME CHANGE: 20100524 8-K 1 form8-kq32018.htm 8-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

__________________

Date of Report (Date of earliest event reported): November 7, 2018

___________________

WRIGHT MEDICAL GROUP N.V.

(Exact name of registrant as specified in its charter)



The Netherlands	1-35065	98-0509600
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)



Prins Bernhardplein 200 1097 JB Amsterdam, The Netherlands	None
(Address of principal executive offices)	(Zip Code)

(+ 31) 20 521 4777

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

TABLE OF CONTENTS



Item 2.02. Results of Operations and Financial Condition
Item 9.01. Financial Statements and Exhibits
Signature
Ex 99.1

Item 2.02. Results of Operations and Financial Condition.

On November 7, 2018, Wright Medical Group N.V. (Wright) issued a press release announcing financial results for the quarter ended September 30, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

Unless the context otherwise requires, references to "Wright," the "company," "we," "our" or "us" in this report refer to Wright Medical Group N.V. and its subsidiaries. References to "legacy Wright" refer to Wright Medical Group, Inc. and its subsidiaries and references to "legacy Tornier" refer to Tornier N.V. and its subsidiaries, in each case prior to the merger between Wright Medical Group, Inc. and Tornier N.V. (the merger or the Wright/Tornier merger).

Wright is furnishing the information contained in this report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the United States Securities and Exchange Commission (SEC). This information shall not be deemed to be filed with the SEC for purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the United States Securities Act of 1933, as amended (Securities Act), except as expressly set forth by specific reference in such filing. By filing this report and furnishing this information, Wright makes no admission as to the materiality of any information contained in this report, including Exhibit 99.1. This report shall not be incorporated into any future filings by Wright under the Securities Act or the Exchange Act.

To supplement our consolidated financial statements prepared in accordance with United States generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, several of which are included in the press release furnished as Exhibit 99.1 to this report. The press release includes the following non-GAAP financial measures: net sales, excluding the impact of foreign currency; net income, as adjusted; EBITDA, as adjusted; gross margin, as adjusted; earnings, as adjusted; and earnings, as adjusted, per diluted share. In each case, our non-GAAP financial measures refer to results from continuing operations.

For internal budgeting and resource allocation process, our management uses financial information that does not include:


1.	non-cash interest expense on convertible notes;


2.	non-cash loss on extinguishment of debt;


3.	mark-to-market adjustments of derivatives;


4.	transaction and transition costs;


5.	non-cash foreign currency translation charges;


6.	BioMimetic contingent value right (CVR) mark-to-market adjustments;


7.	contingent consideration fair value adjustment;


8.	tax benefit related to realizability of net operating losses;


9.	the U.S. tax provision (benefit) recognized in continuing operations resulting from income from discontinued operations; and


10.	income tax effects of the foregoing.

Additionally, for internal budgeting process and evaluation of net sales performance, management uses net sales on a constant currency basis. To measure net sales on a constant currency basis, it is necessary to remove the impact of changes in foreign currency exchange rates, which affects the comparability and trend of net sales. Net sales, on a constant currency basis, is calculated by translating current period results at prior period average foreign currency exchange rates.

For internal budgeting and resource allocation process, management also uses EBITDA, EBITDA, as adjusted, non-GAAP earnings, as adjusted, and gross margin, as adjusted. EBITDA is calculated by adding back to net loss from continuing operations charges for interest, provision (benefit) from income taxes, depreciation, and amortization expenses. EBITDA, as adjusted, is calculated by excluding non-cash share-based compensation expense, non-operating income and expense, as well as the applicable adjustments numbered above, from EBITDA. Non-GAAP earnings, as adjusted, is calculated by adding back to net loss from continuing operations charges for non-cash amortization expenses, net of taxes, as well as the applicable adjustments numbered above. Non-GAAP adjusted gross margins are calculated by excluding transaction and transition costs from gross profit from continuing operations and dividing by net sales from continuing operations.

We use these non-GAAP financial measures in making operating decisions because we believe these measures provide meaningful supplemental information regarding our core operational performance and give us a better understanding of how we should invest in research and development activities and how we should allocate resources to both ongoing and prospective business initiatives. We use these measures to help make budgeting and spending decisions, for example, between research and

development and selling, general and administrative expenses. Additionally, management is evaluated on the basis of some of these non-GAAP financial measures when determining achievement of their performance incentive plan compensation targets. Further, these non-GAAP financial measures facilitate management’s internal comparisons to both our historical operating results and to our competitors’ operating results by factoring out potential differences caused by charges not related to our regular, ongoing business, including without limitation, non-cash charges, certain large and unpredictable charges, acquisitions and dispositions, legal settlements, and tax positions.

As described above, we exclude the following items from one or more of our non-GAAP financial measures for the following reasons:

Foreign currency impact on net sales. We excluded the foreign currency impact on net sales compared to prior period from our non-GAAP measure, primarily because it is not reflective of our ongoing operating results, and it is not used by management for internal budgeting process and evaluation of net sales performance. We further believe that excluding this item is useful to investors in that it allows for period-over-period comparability.

Non-cash interest expense on convertible notes. We excluded the non-cash interest expense on convertible notes from our non-GAAP financial measures, primarily because it is a non-cash expense. We believe that it is useful to investors to understand our operational performance, liquidity, and our ability to invest in research and development and to fund acquisitions and capital expenditures. While interest expense associated with the amortization of the debt discount constitutes an ongoing and recurring expense, such expense is excluded from our non-GAAP financial measures because it is not an expense that requires cash settlement and is not used by management to assess the core profitability of our business operations. We further believe that excluding this item from our non-GAAP results is useful to investors in that it allows for period-over-period comparability.

Non-cash loss on extinguishment of debt. We excluded the non-cash loss on extinguishment of debt from our non-GAAP financial measures, primarily because it is not reflective of our ongoing operating results, and it is not used by management to assess the core profitability of our business operations. We further believe that excluding this item from our non-GAAP results is useful to investors in that it allows for period-over-period comparability.

Mark-to-market adjustment of derivatives. We excluded the adjustment of the mark-to-market adjustments on derivatives from our non-GAAP financial measures, primarily because it is not reflective of our ongoing operating results, and it is not used by management to assess the core profitability of our business operations. We further believe that excluding this item from our non-GAAP results is useful to investors in that it allows for period-over-period comparability.

Transaction and transition costs. We excluded the transaction and transition costs associated with acquisitions and mergers, including the Wright/Tornier merger, from our non-GAAP financial measures, primarily because such costs are not reflective of our ongoing operating results and are not used by management to assess the core profitability of our business operations. We further believe that excluding this item from our non-GAAP results is useful to investors in that it allows for period-over-period comparability.

Non-cash foreign currency translation charges. We excluded the non-cash foreign currency translation charges from our non-GAAP financial measures, primarily because such charges are not reflective of our ongoing operating results, and are not used by management to assess the core profitability of our business operations. We further believe that excluding this item from our non-GAAP results is useful to investors in that it allows for period-over-period comparability.

BioMimetic CVR mark-to-market adjustments. We excluded the adjustment of the mark-to-market adjustments on the contingent value rights associated with acquired assets and liabilities from our BioMimetic acquisition from our non-GAAP financial measures, primarily because it is not reflective of our ongoing operating results, and it is not used by management to assess the core profitability of our business operations. We further believe that excluding this item from our non-GAAP results is useful to investors in that such exclusion allows for period-over-period comparability.

Contingent consideration fair value adjustment. We excluded the fair value adjustment of our contingent consideration from our non-GAAP measures, primarily because it is not reflective of our ongoing operating results, and it is not used by management to assess the core profitability of our business operations. We further believe that excluding this item from our non-GAAP results is useful to investors in that it allows for period-over-period comparability.

Tax benefit related to realizability of net operating losses. We excluded a tax benefit related to a change in the realizability of certain U.S. net operating losses following the completion of a tax project from our non-GAAP financial measures, primarily because they are not reflective of our ongoing operating results, and they are not used by management to assess the core

profitability of our business operations. We further believe that excluding these items from our non-GAAP results is useful to investors in that it allows for period-over-period comparability.

U.S. tax provision (benefit) within continuing operations. We excluded the U.S. tax provision (benefit) within continuing operations recorded as a result of the pre-tax gain recognized within discontinued operations due to the previously announced $30.75 million insurance settlement from our non-GAAP measures, primarily because it is not reflective of our ongoing operating results, and it is not used by management to assess the core profitability of our business operations. We further believe that excluding this item from our non-GAAP results is useful to investors in that it allows for period-over-period comparability.

Income tax effects of the foregoing. This amount is used to present each of the amounts described above, except for foreign currency exchange rate impact on net sales, on an after-tax basis consistent with the presentation of net income, as adjusted.

These non-GAAP financial measures are not in accordance with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of our non-GAAP financial measures may differ from the definitions of other companies using the same or similar names limiting, to some extent, the usefulness of such measures for comparison purposes. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with our financial results as determined in accordance with GAAP. These measures should only be used to evaluate our financial results in conjunction with the corresponding GAAP measures. Accordingly, we qualify our use of non-GAAP financial information in a statement when non-GAAP financial information is presented.

All of the historical non-GAAP financial measures used in our press release are reconciled to the most directly comparable GAAP measure. With respect to our 2018 financial guidance regarding adjusted EBITDA from continuing operations and adjusted non-GAAP earnings per share from continuing operations, we cannot provide a quantitative reconciliation to the most directly comparable GAAP measure without unreasonable effort due to our inability to make accurate projections and estimates related to certain information needed to calculate some of the adjustments. However, we have described in the press release the anticipated differences between these non-GAAP financial measures and the most directly comparable GAAP measure qualitatively.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is being filed or furnished with this Current Report on Form 8-K:



Exhibit Number		Description
99.1		Press release issued by Wright Medical Group N.V. on November 7, 2018 announcing financial results for the quarter ended September 30, 2018 (furnished herewith)

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K, including the exhibit hereto, includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “could,” “may,” “will,” “believe,” “estimate,” “continue,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this report include, but are not limited to, statements about the company’s anticipated financial results for 2018, including net sales from continuing operations, adjusted EBITDA from continuing operations and adjusted earnings per share from continuing operations, anticipated continued strong shoulder sales growth and accelerating adoption of our BLUEPRINT enabling technology, and the anticipated success of Cartiva’s SCI and its contribution to growth for our U.S. lower extremities business for the remainder of 2018 and throughout 2019. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this report is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, failure to achieve anticipated financial results for 2018, failure to achieve the anticipated financial benefits of the recent Cartiva acquisition, unanticipated clinical performance issues with Cartiva products or the introduction of competitive products with clinical performance attributes that are superior to Cartiva products, failure to achieve wide market acceptance of the Cartiva products due to clinical, regulatory, cost, reimbursement or other issues, the failure of the company’s 2017 U.S. sales force additions to achieve expected results, delay or failure to drive U.S. lower extremities or biologics sales to anticipated levels;

continued supply constraints; failure to integrate the legacy Wright and Tornier businesses and realize net sales synergies and cost savings from the merger with Tornier or delay in realization thereof; operating costs and business disruption as a result of the merger, including adverse effects on employee retention and sales force productivity and on business relationships with third parties; integration costs; actual or contingent liabilities; adverse effects of diverting resources and attention to providing transition services to the purchaser of the large joints business; the adequacy of the company’s capital resources and need for additional financing; the timing of regulatory approvals and introduction of new products; physician acceptance, endorsement, and use of new products; failure to achieve the anticipated commercial sales of our AUGMENT^® Bone Graft and other new products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims and product recalls; pending and threatened litigation; risks associated with the metal-on-metal master settlement agreement and the settlement agreement with the three settling insurers; risks associated with the subsequent metal-on-metal settlement agreements and ability to obtain the additional new insurance proceeds contingent thereon; risks associated with international operations and expansion; fluctuations in foreign currency exchange rates; other business effects, including the effects of industry, economic or political conditions outside of the company’s control; reliance on independent distributors and sales agencies; competitor activities; changes in tax and other legislation; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended December 31, 2017 filed by Wright with the SEC on February 28, 2018 and subsequent SEC filings by Wright, including without limitation its Quarterly Report on Form 10-Q for the quarter ended July 1, 2018 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 to be filed with the SEC. Investors should not place considerable reliance on the forward-looking statements contained in this report. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this report speak only as of the date of this report, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2018



	WRIGHT MEDICAL GROUP N.V.


	By: /s/ Lance A. Berry
	Name: Lance A. Berry
	Title: Senior Vice President and Chief Financial Officer

EX-99.1 2 wmgi-9302018exhibit991pres.htm EXHIBIT 99.1 Exhibit



FOR IMMEDIATE RELEASE
Investors & Media:
Julie D. Dewey Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V. (901) 290-5817 julie.dewey@wright.com

Wright Medical Group N.V. Reports 2018 Third Quarter Financial Results

Third Quarter 2018 Net Sales of $194 Million, 13.8% as Reported Growth and 14.4% Constant Currency Growth

Third Quarter 2018 Net Loss From Continuing Operations of $36 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $21 Million

Company Increases 2018 Annual Guidance

AMSTERDAM, The Netherlands - November 7, 2018 - Wright Medical Group N.V. (NASDAQ:WMGI) today reported financial results for its third quarter ended September 30, 2018 and increased its 2018 annual guidance. Unless otherwise noted, all net sales growth rates in this release are stated on a constant currency basis.

Net sales totaled $194.1 million during the third quarter ended September 30, 2018, representing 13.8% as reported and 14.4% constant currency growth, an estimated 150 basis point improvement versus the second quarter of 2018. Gross margins were 77.2% during the quarter and were 77.9% on a non-GAAP adjusted basis. Reconciliations of all historical non-GAAP financial measures used in this release to the most comparable GAAP measures can be found in the attached financial tables.

Robert Palmisano, president and chief executive officer, stated, “Our team produced outstanding results across the board in the third quarter, including over 14% constant currency net sales growth, fueled by our new product launches, ongoing rollouts and increased contributions from our sales organization. These results include continued strong performance in our U.S. upper extremities business, which grew 19% in the third quarter, driven by 21% growth in our U.S. shoulder business. We anticipate that continued penetration of our SIMPLICITI shoulder system, our ongoing PERFORM Reversed launch and accelerating adoption of our BLUEPRINT enabling technology will continue to drive market-leading shoulder sales growth in 2018.”

Palmisano commented, “Our U.S. lower extremities growth rate accelerated to 12% in the third quarter, driven by approximately 22% growth in total ankle and a return to market growth in our core lower extremities business. Additionally, the launch of AUGMENT Injectable is off to a strong start and provided an excellent boost to the U.S. biologics business, which grew approximately 11% this quarter, up from 5% in the second quarter of 2018.”

Palmisano further commented, “With the Cartiva acquisition now closed, we significantly strengthened our market-leading lower extremities portfolio by adding Cartiva’s highly differentiated Synthetic Cartilage Implant (SCI), the first and only PMA product for the treatment of great toe osteoarthritis. Supported by compelling clinical performance and the only product of its kind backed by Level I clinical evidence, Cartiva is experiencing rapid commercial adoption and is well positioned for future growth as it addresses large markets with significant unmet needs and strong patient demand. We expect this acquisition to support our growth prospects in our core lower extremities business throughout 2019 and beyond.”

Net loss from continuing operations for the third quarter of 2018 totaled $35.8 million, or $(0.32) per diluted share.

The company’s net loss from continuing operations for the third quarter of 2018 included the after-tax impacts of non-cash interest expense of $12.3 million related to its convertible notes, an unrealized loss of $3.4 million related

to mark-to-market adjustments on contingent value rights (CVRs) issued in connection with the BioMimetic acquisition, a $2.2 million U.S. tax provision within continuing operations recorded as a result of the year to date pre-tax gain recognized within discontinued operations due to the previously announced $30.75 million insurance settlement, $2.0 million of transaction and transition costs associated with the Cartiva acquisition and non-cash inventory provisions, and non-cash foreign currency translation charges of $0.2 million.

The company's third quarter 2018 non-GAAP net loss from continuing operations, as adjusted for the above items, was $15.5 million. The company's third quarter 2018 non-GAAP adjusted EBITDA from continuing operations, as defined in the non-GAAP to GAAP reconciliation provided later in this release, was $20.6 million. The attached financial tables include reconciliations of all historical non-GAAP measures to the most comparable GAAP measures.

Cash and cash equivalents totaled $694.9 million as of the end of the third quarter of 2018. $435 million of this cash balance was paid out on October 10, 2018 at the close of the Cartiva acquisition.

Palmisano concluded, “We are increasing our full-year guidance to reflect both the overperformance in our existing business as well as the addition of Cartiva. I believe we are set up well for the remainder of 2018 and next year. Our end markets remain healthy and fast growing, our gross margins are outstanding, and our new product pipeline is full of innovative and commercially impactful products and surgical solutions across all parts of our business.”

Outlook

Wright today raised its full-year 2018 net sales guidance, excluding the impact of the Cartiva acquisition, to approximately $825 million to $828 million, from its previous guidance of approximately $812 million to $822 million. This guidance range assumes foreign currency exchange rates for the remainder of the year that are generally in line with current rates. In addition, this range implies full-year 2018 constant currency net sales growth of 11% to 12%, excluding the estimated $9 million impact of the four fewer selling days in fourth quarter of 2018. Additionally, the company is providing guidance on the impact of the Cartiva acquisition. From the date of closing, which was October 10, 2018, Cartiva is anticipated to provide approximately $7 million of net sales in 2018, resulting in as reported net sales guidance of $832 million to $835 million.

The company is raising its full-year 2018 non-GAAP adjusted EBITDA from continuing operations guidance, as described in the non-GAAP reconciliation provided later in this release, to a range of $110 million to $116 million from its previous range of $106 million to $113 million. Cartiva is estimated to be roughly neutral to 2018 non-GAAP adjusted EBITDA on an as reported basis.

The company expects its non-GAAP adjusted earnings per share from continuing operations, including share-based compensation, as described in the non-GAAP to GAAP reconciliation provided later in this release, for full-year 2018 to be a loss of $0.08 to $0.03 per diluted share.

The company estimates approximately 112.6 million diluted weighted average ordinary shares outstanding for fiscal year 2018, and 127.2 million non-GAAP adjusted diluted weighted average ordinary shares outstanding for the fourth quarter of 2018.

The company's non-GAAP adjusted EBITDA from continuing operations target is measured by adding back to net loss from continuing operations charges for interest, income taxes, depreciation and amortization expenses, non-cash share-based compensation expense and non-operating income and expense. Additionally, the company’s adjusted EBITDA from continuing operations target excludes possible future acquisitions; other material future business developments; and due diligence, transaction and transition costs associated with acquisitions and divestitures.

The company’s non-GAAP adjusted earnings per share from continuing operations target is measured by adding back to net loss from continuing operations non-cash interest expense associated with the convertible notes; due diligence, transaction and transition costs associated with acquisitions and divestitures; mark-to-market adjustments to CVRs; non-cash mark-to-market derivative adjustments; non-cash gains and losses associated with foreign currency translation of balances denominated in foreign currencies; and charges for non-cash amortization expenses,

net of taxes. Note that as a result of the company’s relatively low effective tax rate due to the valuation allowance impacting a substantial portion of the company’s income/loss, the company is currently estimating the tax effect on amortization expense at 0%. Further, this non-GAAP adjusted earnings per share from continuing operations target excludes possible future acquisitions and other material future business developments.

All the historical non-GAAP financial measures used in this release are reconciled to the most directly comparable GAAP measures. With respect to the company’s 2018 financial guidance regarding non-GAAP adjusted EBITDA from continuing operations and non-GAAP adjusted earnings per share from continuing operations, however, the company cannot provide a quantitative reconciliation to the most directly comparable GAAP measures without unreasonable effort due to its inability to make accurate projections and estimates related to certain information needed to calculate some of the adjustments as described above, including the foreign currency fluctuations and market driven fair value adjustments to CVRs and derivatives. The anticipated differences between these non-GAAP financial measures and the most directly comparable GAAP measure are described above qualitatively.

The company's anticipated ranges for net sales from continuing operations, non-GAAP adjusted EBITDA from continuing operations, and non-GAAP adjusted earnings per share from continuing operations are forward-looking statements, as are any other statements that anticipate or aspire to future events or performance. They are subject to various risks and uncertainties that could cause the company's actual results to differ materially from the anticipated targets. The anticipated targets are not predictions of the company's actual performance. See the cautionary information about forward-looking statements in the “Cautionary Note Regarding Forward-Looking Statements” section of this release.

Supplemental Financial Information

To view the third quarter of 2018 supplemental financial information, visit ir.wright.com. For historical information on Wright Medical Group N.V. segment reporting changes and non-GAAP combined pro forma financial information, please refer to the presentation posted on Wright’s website at ir.wright.com in the “Financial Information” section.

Internet Posting of Information

Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com. The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.

Conference Call and Webcast

As previously announced, Wright will host a conference call starting at 3:30 p.m. Central Time today. The live dial-in number for the call is (844) 295-9436 (U.S.) / (574) 990-1040 (Outside U.S.). The participant passcode for the call is “Wright.” A simultaneous webcast of the call will be available via Wright’s corporate website at www.wright.com.

A replay of the call will be available beginning at 5:30 p.m. Central Time on November 7, 2018 through November 14, 2018. To hear this replay, dial (855) 859-2056 (U.S.) / (404) 537-3406 (Outside U.S.) and enter code 9295624. A replay of the conference call will also be available via the internet starting today and continuing for at least 12 months. To access a replay of the conference call via the internet, go to the “Investor Relations - Presentations/Calendar” section of the company’s corporate website located at www.wright.com.

The conference call may include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this release, the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) today, or otherwise available in the “Investor Relations - Supplemental Financial Information” section of the company's corporate website located at www.wright.com.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the “Cautionary Note Regarding Forward-Looking Statements” section of this release.

About Wright Medical Group N.V.

Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide. Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. For more information about Wright, visit www.wright.com.

™ and ® denote trademarks and registered trademarks of Wright Medical Group N.V. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles, the company uses certain non-GAAP financial measures in this release. Reconciliations of the historical non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. Wright’s non-GAAP financial measures include net sales, excluding the impact of foreign currency; net income, as adjusted; EBITDA, as adjusted; gross margin, as adjusted; earnings, as adjusted; and earnings, as adjusted, per diluted share, in each case, from continuing operations. The company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the company's operations, period over period. Wright’s non-GAAP financial measures exclude such items as non-cash interest expense related to the company's convertible notes, non-cash loss on extinguishment of debt, transaction and transition costs, net gains and losses on mark-to-market adjustments on CVRs and derivative assets and liabilities, net non-cash gains and losses on foreign currency translation all of which may be highly variable, difficult to predict and of a size that could have substantial impact on the company's reported results of operations for a period. It is for this reason that the company cannot provide without unreasonable effort a quantitative reconciliation to the most directly comparable GAAP measures for its 2018 financial guidance regarding non-GAAP adjusted EBITDA from continuing operations and non-GAAP adjusted earnings per share from continuing operations. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “could,” “may,” “will,” “believe,” “estimate,” “continue,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this release include, but are not limited to, statements about the company’s anticipated financial results for 2018, including net sales from continuing operations, adjusted EBITDA from continuing operations and adjusted earnings per share from continuing operations, anticipated continued strong shoulder sales growth and accelerating adoption of our BLUEPRINT enabling technology, and the anticipated success of Cartiva’s SCI and its contribution to growth for our U.S. lower extremities business for the remainder of 2018 and throughout 2019. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, failure to achieve anticipated financial results for 2018, failure to achieve the anticipated financial benefits of the recent Cartiva acquisition, unanticipated clinical performance issues with Cartiva products or the introduction of competitive products with clinical performance attributes that are superior to Cartiva products, failure to achieve wide market acceptance of the Cartiva products due to clinical, regulatory, cost, reimbursement or other issues, the failure of the company’s 2017 U.S. sales force additions to achieve expected results, delay or failure to drive U.S. lower extremities or biologics sales to

anticipated levels; continued supply constraints; failure to integrate the legacy Wright and Tornier businesses and realize net sales synergies and cost savings from the merger with Tornier or delay in realization thereof; operating costs and business disruption as a result of the merger, including adverse effects on employee retention and sales force productivity and on business relationships with third parties; integration costs; actual or contingent liabilities; adverse effects of diverting resources and attention to providing transition services to the purchaser of the large joints business; the adequacy of the company’s capital resources and need for additional financing; the timing of regulatory approvals and introduction of new products; physician acceptance, endorsement, and use of new products; failure to achieve the anticipated commercial sales of our AUGMENT^® Bone Graft and other new products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims and product recalls; pending and threatened litigation; risks associated with the metal-on-metal master settlement agreement and the settlement agreement with the three settling insurers; risks associated with the subsequent metal-on-metal settlement agreements and ability to obtain the additional new insurance proceeds contingent thereon; risks associated with international operations and expansion; fluctuations in foreign currency exchange rates; other business effects, including the effects of industry, economic or political conditions outside of the company’s control; reliance on independent distributors and sales agencies; competitor activities; changes in tax and other legislation; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended December 31, 2017 filed by Wright with the SEC on February 28, 2018 and subsequent SEC filings by Wright, including without limitation its Quarterly Report on Form 10-Q for the quarter ended July 1, 2018 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 to be filed with the SEC. Investors should not place considerable reliance on the forward-looking statements contained in this release. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

--Tables Follow--

Wright Medical Group N.V.

Condensed Consolidated Statements of Operations

(dollars in thousands, except per share data--unaudited)



	Three months ended						Nine months ended
	September 30, 2018			September 24, 2017			September 30, 2018			September 24, 2017
Net sales	$	194,106		$	170,503		$	598,043		$	527,387
Cost of sales	44,307			38,421			131,004			113,669
Gross profit	149,799			132,082			467,039			413,718
Operating expenses:
Selling, general and administrative	139,223			131,421			417,297			392,073
Research and development	13,829			11,992			42,393			36,971
Amortization of intangible assets	5,881			7,178			19,031			21,574
Total operating expenses	158,933			150,591			478,721			450,618
Operating loss	(9,134		)	(18,509		)	(11,682		)	(36,900		)
Interest expense, net	19,753			18,978			60,243			55,512
Other expense, net	3,902			5,457			75,649			6,875
Loss from continuing operations before income taxes	(32,789		)	(42,944		)	(147,574		)	(99,287		)
Provision (benefit) for income taxes	3,040			(8,822		)	(1,217		)	(7,498		)
Net loss from continuing operations	$	(35,829	)	$	(34,122	)	$	(146,357	)	$	(91,789	)
(Loss) income from discontinued operations, net of tax	(6,696		)	(97,748		)	10,620			(139,942		)
Net loss	$	(42,525	)	$	(131,870	)	$	(135,737	)	$	(231,731	)

Net loss from continuing operations per share, basic and diluted	$	(0.32	)	$	(0.33	)	$	(1.35	)	$	(0.88	)
Net (loss) income from discontinued operations per share, basic and diluted	$	(0.06	)	$	(0.93	)	$	0.10		$	(1.34	)

Net loss per share, basic and diluted	$	(0.38	)	$	(1.26	)	$	(1.25	)	$	(2.22	)

Weighted-average number of shares outstanding-basic and diluted	113,043			104,836			108,348			104,292

Wright Medical Group N.V.

Consolidated Net Sales Analysis

(dollars in thousands--unaudited)



	Three months ended						Nine months ended
	September 30, 2018		September 24, 2017		% change		September 30, 2018		September 24, 2017		% change
U.S.
Lower extremities	$	57,602	$	51,417	12.0	%	$	173,889	$	161,228	7.9	%
Upper extremities	65,334		54,788		19.2	%	203,163		168,280		20.7	%
Biologics	20,654		18,640		10.8	%	59,053		56,547		4.4	%
Sports med & other	1,975		2,019		(2.2	)%	5,828		5,899		(1.2	)%
Total U.S.	$	145,565	$	126,864	14.7	%	$	441,933	$	391,954	12.8	%

International
Lower extremities	$	13,501	$	13,963	(3.3	)%	$	44,508	$	42,372	5.0	%
Upper extremities	25,681		21,197		21.2	%	84,412		66,606		26.7	%
Biologics	6,549		5,193		26.1	%	18,388		15,492		18.7	%
Sports med & other	2,810		3,286		(14.5	)%	8,802		10,963		(19.7	)%
Total International	$	48,541	$	43,639	11.2	%	$	156,110	$	135,433	15.3	%

Global
Lower extremities	$	71,103	$	65,380	8.8	%	$	218,397	$	203,600	7.3	%
Upper extremities	91,015		75,985		19.8	%	287,575		234,886		22.4	%
Biologics	27,203		23,833		14.1	%	77,441		72,039		7.5	%
Sports med & other	4,785		5,305		(9.8	)%	14,630		16,862		(13.2	)%
Total net sales	$	194,106	$	170,503	13.8	%	$	598,043	$	527,387	13.4	%

Wright Medical Group N.V.

Supplemental Net Sales Information

(unaudited)



	Three months ended September 30, 2018 net sales growth/(decline)
	U.S. as reported	Int'l constant currency	Int'l as reported	Global constant currency	Global as reported
Product line
Lower extremities	12%	(1%)	(3%)	9%	9%
Upper extremities	19%	23%	21%	20%	20%
Biologics	11%	29%	26%	15%	14%
Sports med & other	(2%)	(14%)	(14%)	(9%)	(10%)
Total net sales	15%	13%	11%	14%	14%



	Nine months ended September 30, 2018 net sales growth/(decline)
	U.S. as reported	Int'l constant currency	Int'l as reported	Global constant currency	Global as reported
Product line
Lower extremities	8%	1%	5%	6%	7%
Upper extremities	21%	20%	27%	21%	22%
Biologics	4%	18%	19%	7%	7%
Sports med & other	(1%)	(25%)	(20%)	(16%)	(13%)
Total net sales	13%	10%	15%	12%	13%

Wright Medical Group N.V.

Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share

(dollars in thousands, except per share data--unaudited)



	Three months ended						Nine months ended
	September 30, 2018			September 24, 2017			September 30, 2018			September 24, 2017
Net loss from continuing operations, as reported	$	(35,829	)	$	(34,122	)	$	(146,357	)	$	(91,789	)
Net loss from continuing operations per share, as reported	$	(0.32	)	$	(0.33	)	$	(1.35	)	$	(0.88	)
Reconciling items:
Non-cash interest expense on convertible notes ¹	12,326			11,494			36,613			33,743
Non-cash loss on extinguishment of debt ²	—			—			39,935			—
Derivatives mark-to-market adjustments ²	(230		)	(199		)	34,343			(4,163		)
Transaction and transition costs	1,952			3,311			4,187			9,485
Foreign currency translation expense ²	238			—			2,894			—
CVR mark-to-market adjustments ²	3,363			4,485			(3,084		)	6,721
Contingent consideration fair value adjustment ²	327			133			1,106			309
Tax benefit related to realizability of net operating losses	—			(8,928		)	—			(8,928		)
U.S. tax provision (benefit) resulting from income from discontinued operations	2,216			—			(3,967		)	—
Tax effect of reconciling items ³	106			—			965			(70		)
Non-GAAP net loss from continuing operations, as adjusted	$	(15,531	)	$	(23,826	)	$	(33,365	)	$	(54,692	)
Add back amortization of intangible assets	5,881			7,178			19,031			21,574
Adjusted non-GAAP earnings	$	(9,650	)	$	(16,648	)	$	(14,334	)	$	(33,118	)
Weighted-average basic shares outstanding	113,043			104,836			108,348			104,292
Adjusted non-GAAP earnings per share	$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.32	)

_______________________________


¹	Impacting interest expense, net


²	Impacting other expense, net


³	Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

Wright Medical Group N.V.

Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations

(dollars in thousands--unaudited)



	Three months ended						Nine months ended
	September 30, 2018			September 24, 2017			September 30, 2018			September 24, 2017
Net loss from continuing operations	$	(35,829	)	$	(34,122	)	$	(146,357	)	$	(91,789	)
Interest expense, net	19,753			18,978			60,243			55,512
Provision (benefit) from income taxes	3,040			(8,822		)	(1,217		)	(7,498		)
Depreciation	14,604			15,000			42,986			42,124
Amortization	5,881			7,178			19,031			21,574
Non-GAAP EBITDA	$	7,449		$	(1,788	)	$	(25,314	)	$	19,923
Reconciling items impacting EBITDA:
Non-cash share-based compensation expense	7,257			5,445			18,336			14,131
Other expense, net	3,902			5,457			75,649			6,875
Transaction and transition costs	1,952			3,311			4,187			9,485
Non-GAAP adjusted EBITDA	$	20,560		$	12,425		$	72,858		$	50,414
Net sales from continuing operations	194,106			170,503			598,043			527,387
Non-GAAP adjusted EBITDA margin	10.6		%	7.3		%	12.2		%	9.6		%

Wright Medical Group N.V.

Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations

(dollars in thousands--unaudited)



	Three months ended						Nine months ended
	September 30, 2018			September 24, 2017			September 30, 2018			September 24, 2017
Gross profit from continuing operations, as reported	$	149,799		$	132,082		$	467,039		$	413,718
Gross margins from continuing operations, as reported	77.2		%	77.5		%	78.1		%	78.4		%
Reconciling items impacting gross profit:
Transaction and transition costs	1,385			1,310			3,620			1,995
Non-GAAP gross profit from continuing operations, as adjusted	$	151,184		$	133,392		$	470,659		$	415,713
Net sales from continuing operations	194,106			170,503			598,043			527,387
Non-GAAP adjusted gross margins from continuing operations	77.9		%	78.2		%	78.7		%	78.8		%

Wright Medical Group N.V.

Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results

(dollars in thousands--unaudited)



	Three months ended						Nine months ended
	September 30, 2018			September 24, 2017			September 30, 2018			September 24, 2017
Net sales	$	194,106		$	170,503		$	598,043		$	527,387

Selling, general and administrative expense, as reported	$	139,223		$	131,421		$	417,297		$	392,073
Selling, general and administrative expense as a percentage of net sales, as reported	71.7		%	77.1		%	69.8		%	74.3		%
Reconciling items impacting selling, general and administrative expense:
Transaction and transition costs - selling, general and administrative	567			1,878			567			7,267
Selling, general and administrative expense, as adjusted	$	138,656		$	129,543		$	416,730		$	384,806
Selling, general and administrative expense as a percentage of net sales, as adjusted	71.4		%	76.0		%	69.7		%	73.0		%

Research & development expense, as reported	$	13,829		$	11,992		$	42,393		$	36,971
Research & development expense as a percentage of net sales, as reported	7.1		%	7.0		%	7.1		%	7.0		%
Reconciling items impacting research & development expense:
Transaction and transition costs - research & development	—			122			—			222
Research & development expense, as adjusted	$	13,829		$	11,870		$	42,393		$	36,749
Research & development expense as a percentage of net sales, as adjusted	7.1		%	7.0		%	7.1		%	7.0		%

Wright Medical Group N.V.

Condensed Consolidated Balance Sheets

(dollars in thousands--unaudited)



	September 30, 2018		December 31, 2017
Assets
Current assets:
Cash and cash equivalents	$	694,903	$	167,740
Accounts receivable, net	122,595		130,610
Inventories	179,494		168,144
Prepaid expenses and other current assets ¹	326,743		100,400
Total current assets	1,323,735		566,894

Property, plant and equipment, net	221,175		212,379
Goodwill and intangible assets, net	1,130,966		1,164,663
Other assets ¹	163,419		184,788
Total assets	$	2,839,295	$	2,128,724

Liabilities and shareholders' equity
Current liabilities:
Accounts payable	$	45,057	$	41,831
Accrued expenses and other current liabilities ¹	506,322		314,558
Current portion of long-term obligations ¹	514,930		58,906
Total current liabilities	1,066,309		415,295
Long-term obligations ¹	586,582		836,208
Other liabilities ¹	227,906		288,525
Total liabilities	1,880,797		1,540,028

Shareholders' equity	958,498		588,696
Total liabilities and shareholders' equity	$	2,839,295	$	2,128,724

___________________________

As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes and the fair value of the 2021 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2021 Notes Hedges were classified as current assets as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017. Additionally, the holders of the 2020 Notes will have the ability to begin converting their 2020 Notes beginning August 15, 2019 through their maturity. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes and the fair value of the 2020 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2020 Notes Hedges were classified as current assets as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017.

###

GRAPHIC 3 image0a05.jpg begin 644 image0a05.jpg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end